)
)
Skye Bioscience Investor Relations Material
Latest events
Q3 2024
Skye Bioscience
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Skye Bioscience Inc
Access all reports
Skye Bioscience, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutic solutions targeting the endocannabinoid system (ECS). The company's primary focus is on conditions such as obesity, chronic kidney disease, and glaucoma. Skye's portfolio includes drug candidates like nimacimab, a monoclonal antibody that acts as a CB1 receptor inhibitor, and SBI-100 Ophthalmic Emulsion, designed to reduce intraocular pressure in glaucoma patients. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Latest articles
)
James Quincey: Coca-Cola Chairman and CEO
James Quincey has dedicated nearly three decades to The Coca-Cola Company, rising through the ranks to become CEO and Chairman of the company.
11 Mar 2025
)
PepsiCo: From Pepsi and Gatorade to Doritos and Lay's
PepsiCo has grown from a soda company into a global leader in food and beverages, with a portfolio of over 200 brands, including Pepsi, Lay's, and Gatorade.
11 Mar 2025
)
Bob Iger: Disney's Visionary CEO
Bob Iger is a legend in the entertainment industry, known for his visionary leadership and as one of the most influential CEOs in Disney's history.
10 Mar 2025
Ticker symbol
SKYE
Country
🇺🇸 United States